Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 5.1. Therapeutic Area
- 5.2. Drug Class
- 5.3. Patient Demographics
- 5.4. Route of Administration
- 5.5. Distribution Channel
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
- 6.1. Infectious Diseases
- 6.1.1. HIV/AIDS
- 6.1.2. Tuberculosis (TB)
- 6.1.3. Hepatitis C
- 6.2. Chronic Diseases
- 6.2.1. Hypertension
- 6.2.2. Asthma & COPD
- 6.2.3. Cardiovascular Diseases
- 6.3. Cystic Fibrosis (CF)
- 6.4. Cancer
- 6.4.1. Lung Cancer
- 6.4.2. Colorectal Cancer
- 6.4.3. Other solid and hematological cancers
- 6.5. Autoimmune Disorders
- 6.5.1. Rheumatoid Arthritis
- 6.5.2. Psoriasis
- 6.6. Neurological Disorders
- 6.6.1. Alzheimer’s Disease
- 6.6.2. Multiple Sclerosis
- 6.1. Infectious Diseases
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
- 7.1. Antiretroviral Agents (HIV, TB)
- 7.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 7.1.2. Protease Inhibitors (PIs)
- 7.1.3. Integrase Inhibitors
- 7.2. Targeted Cancer Therapies
- 7.2.1. Kinase Inhibitors
- 7.2.2. PARP Inhibitors
- 7.3. Immunomodulators (Autoimmune Diseases, Cancers)
- 7.4. Anti-inflammatory Drugs (Asthma, COPD)
- 7.5. Gene Modulators (e.g., CFTR modulators in cystic fibrosis)
- 7.1. Antiretroviral Agents (HIV, TB)
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Patient Demographics
- 8.1. Pediatrics
- 8.2. Adults
- 8.3. Geriatrics
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
- 9.1. Oral Therapies
- 9.2. Intravenous (IV)
- 9.3. Subcutaneous (SC)
- 9.4. Inhalation-based Therapies: Nebulizers, Inhalers
- 9.5. Topical Applications
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
- 10.1. Hospital Pharmacies
- 10.2. Retail Pharmacies
- 10.3. Online Pharmacies
- 10.4. Specialty Clinics
- 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. East Asia
- 11.6. South Asia & Pacific
- 11.7. MEA
- 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. MEA Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 19. Sales Forecast 2024 to 2034 by Therapeutic Area, Drug Class, Patient Demographics, Route of Administration, and Distribution Channel for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Vertex Pharmaceuticals
- 21.2. Novartis
- 21.3. AstraZeneca
- 21.4. GlaxoSmithKline (GSK)
